Evidence map›Paper›PMID 25605839›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis?

Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Manuel Sobrinho-Simões, Paula Soares

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. TERT genetic polymorphismFrontiers in surgery · 2022
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Diverse regulatory manners of human telomerase reverse transcriptase.Cell communication and signaling : CCS · 2019
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Miguel MeloInstitute of Molecular Pathology and Immunology; University of Porto, Porto; University and Hospital Center of Coimbra; University of Coimbra, Coimbra, Portugal.
Adriana Gaspar da RochaInstitute of Molecular Pathology and Immunology; University of Porto, Porto, Portugal.
João VinagreInstitute of Molecular Pathology and Immunology; Institute of Biomedical Sciences of Abel Salazar, University of Porto, Porto, Portugal.
Manuel Sobrinho-SimõesInstitute of Molecular Pathology and Immunology; University of Porto; Hospital S. João, Porto, Portugal.
Paula SoaresInstitute of Molecular Pathology and Immunology; University of Porto, Porto, Portugal psoares@ipatimup.pt.
Universidade do Porto · PTHospital de São João · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationCarcinomaFemaleHumansMaleProto-Oncogene Proteins B-rafTelomeraseThyroid NeoplasmsProto-Oncogene Proteins B-rafTelomerase

Identifiers

PMID25605839
OpenAlexW2137241495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.